1Aguiar PH,Agner C,Simm R,et al.p53 Protein expression in meningioma-a clinicopathologic study of 55 patients[J].Neurosurg Rev,2002,25(4):252-257.
2Tse JY,Ng HK,Lo KW,et al.Analysis of cell cycle regulators:p16NK4a,Rb,and CDK4 in low and high-grade meningiomas[J].Hum Pathol,1998,29(11):1200-1207.
3Bostrom J,Meyer-Puttlitz B,Wolter M,et al.Alterations of the tumor suppressor genes CDKN 2A (p16NK4a),p14(ARF),p15,CDKN 2B (p15NK4b),and CDKN 2C (p18NK4c) in atypical and anaplastic meningiomas[J].Am J Patho,2001,159(2):661-669.
4Szijan I,Rochefort D,Bruder C,et al.NF2 tumor suppressor gene:a comprehensive and efficient detection of somatic mutations by denaturing HPlC and microarry-CGH[J].Neuromolecular Med,2003,3(1):41-52.
5Verheijen FM,Sprong M,Jacobs HM,et al.Progesterone receptor isoform expression in human meningiomas[J].Eur J Cancer,2001,37(12):1488-1495.
6Konstantinidou AE,Korkolopoulou P,Mahera H,et al.Hormone receptors in non-malignant meningiomas correlate with apoptosis,cell proliferation and recurrence free survival[J].Histopathol,2003,43(3):280-290.
7Platt SR,Scase TJ,Adams V,et al,Vascular endo the lial growth factor expressioc in canine intracranial meningio mas and association with patient survival[J].J Inern Med,2006,20(3):663-668.
8Simon M,Park TW,Leuenroth S,et al.Telomerase activity and expression of the telomerase catalytic subunit,hTERT,in meningioma progression[J].J Neurosurg,2000,92(5):832-840.
